171 related articles for article (PubMed ID: 38572589)
1. m
Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
[TBL] [Abstract][Full Text] [Related]
2. KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma.
Cai H; Liang J; Jiang Y; Wang Z; Li H; Wang W; Wang C; Hou J
J Exp Clin Cancer Res; 2024 Mar; 43(1):69. PubMed ID: 38443991
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2.
Wen D; Xiao H; Gao Y; Zeng H; Deng J
Mol Cancer; 2024 May; 23(1):116. PubMed ID: 38822351
[TBL] [Abstract][Full Text] [Related]
4. LINC00987 knockdown inhibits the progression of acute myeloid leukemia by suppressing IGF2BP2-mediated PA2G4 expression.
Liu C; Ma Y; Wang R; Su G
Anticancer Drugs; 2022 Jan; 33(1):e207-e217. PubMed ID: 34407052
[TBL] [Abstract][Full Text] [Related]
5. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability.
Zhang N; Shen Y; Li H; Chen Y; Zhang P; Lou S; Deng J
Exp Mol Med; 2022 Feb; 54(2):194-205. PubMed ID: 35217832
[TBL] [Abstract][Full Text] [Related]
6. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
[TBL] [Abstract][Full Text] [Related]
7. Dynamic alterations of the transcriptome-wide m
Zhang J; Liu T; Wang Y; Yan X; Li Y; Xu F; Zhang R
Genomics; 2023 Nov; 115(6):110725. PubMed ID: 37820824
[TBL] [Abstract][Full Text] [Related]
8. Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.
Fang F; Lu J; Sang X; Tao YF; Wang JW; Zhang ZM; Zhang YP; Li XL; Xie Y; Wu SY; Chu XR; Li G; Wu D; Chen YL; Yu JJ; Jia SQ; Feng CX; Tian YY; Li ZH; Ling J; Hu SY; Pan J
J Exp Clin Cancer Res; 2022 Jul; 41(1):225. PubMed ID: 35842703
[TBL] [Abstract][Full Text] [Related]
9. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
[TBL] [Abstract][Full Text] [Related]
10. RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.
Fan J; Zhuang M; Fan W; Hou M
PeerJ; 2023; 11():e15706. PubMed ID: 37663284
[TBL] [Abstract][Full Text] [Related]
11. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
12. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
[TBL] [Abstract][Full Text] [Related]
13. Chidamide inhibits cell glycolysis in acute myeloid leukemia by decreasing N6-methyladenosine-related GNAS-AS1.
Hu C; Fu X; Li S; Chen C; Zhao X; Peng J
Daru; 2024 Jun; 32(1):11-24. PubMed ID: 37926762
[TBL] [Abstract][Full Text] [Related]
14. FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer.
Zhou Z; Zhang B; Deng Y; Deng S; Li J; Wei W; Wang Y; Wang J; Feng Z; Che M; Yang X; Meng J; Li Y; Hu Y; Sun Y; Wen L; Huang F; Sheng Y; Wan C; Yang K
J Exp Clin Cancer Res; 2024 Jan; 43(1):34. PubMed ID: 38281999
[TBL] [Abstract][Full Text] [Related]
15. Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
Zhang L; Su X
Cell Oncol (Dordr); 2022 Jun; 45(3):355-365. PubMed ID: 35579750
[TBL] [Abstract][Full Text] [Related]
16. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
Yi J; Peng F; Zhao J; Gong X
Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
[TBL] [Abstract][Full Text] [Related]
17. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
18. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
[TBL] [Abstract][Full Text] [Related]
19. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.
Zhu K; Gao T; Wang Z; Zhang L; Tan K; Lv Z
Cell Death Discov; 2023 May; 9(1):151. PubMed ID: 37156775
[TBL] [Abstract][Full Text] [Related]
20. IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia.
He X; Li W; Liang X; Zhu X; Zhang L; Huang Y; Yu T; Li S; Chen Z
Cell Physiol Biochem; 2018; 51(4):1945-1956. PubMed ID: 30513526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]